The Role of the Dietitian in Weight Management of Adults With Obesity Without Diabetes Using Glucagon Like Peptide-1 Agonist Receptors: A Systematic Review and Meta-Analysis of Randomised Controlled Clinical Trials.

IF 2.2 Q3 ENDOCRINOLOGY & METABOLISM
Clinical Obesity Pub Date : 2025-06-18 DOI:10.1111/cob.70030
Israa Moetaz, Suhad Abumweis, Sarah Alqadi, Mahmoud AbuGhoush
{"title":"The Role of the Dietitian in Weight Management of Adults With Obesity Without Diabetes Using Glucagon Like Peptide-1 Agonist Receptors: A Systematic Review and Meta-Analysis of Randomised Controlled Clinical Trials.","authors":"Israa Moetaz, Suhad Abumweis, Sarah Alqadi, Mahmoud AbuGhoush","doi":"10.1111/cob.70030","DOIUrl":null,"url":null,"abstract":"<p><p>The aims are (1) to identify and interpret the role of registered dietitian in clinical trials on the efficacy of glucagon like peptide-1 (GLP-1) agonists in adult individuals with obesity but without diabetes, and (2) to quantify the effect of GLP-1 agonists on body weight loss in adult individuals with obesity but without diabetes. An electronic search using PubMed and Scopus was implemented to locate eligible randomised clinical trials. Data extraction and quality assessment were conducted for 13 studies that met the inclusion criteria. Medical nutrition therapy (MNT) steps were evaluated based on the registered dietitian (RD) interventions and procedures that are included in six studies. Data analysis was carried out using specialised software. The meta-analysis results showed pooled mean differences in weight change of -5.4 kg (95% CI: -5.8, -5.0), in waist circumference change of -5.5 cm (95% CI: -7.7, -3.25), and in weight loss as a percentage from baseline of -7.75% (95% CI: -11.1, -4.3). Quality assessment and bias of each study have been reported. Nutrition practice guidelines and MNT are also listed to include screening, assessment, intervention, and monitoring. Based on current available evidence, using GLP-1 agonists for weight loss shows their effectiveness to reduce weight and waist circumference. However, further incorporation of RD in trials will help in understanding the sole effect of MNT in treating obesity using GLP-1 agonists.</p>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":" ","pages":"e70030"},"PeriodicalIF":2.2000,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Obesity","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/cob.70030","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

The aims are (1) to identify and interpret the role of registered dietitian in clinical trials on the efficacy of glucagon like peptide-1 (GLP-1) agonists in adult individuals with obesity but without diabetes, and (2) to quantify the effect of GLP-1 agonists on body weight loss in adult individuals with obesity but without diabetes. An electronic search using PubMed and Scopus was implemented to locate eligible randomised clinical trials. Data extraction and quality assessment were conducted for 13 studies that met the inclusion criteria. Medical nutrition therapy (MNT) steps were evaluated based on the registered dietitian (RD) interventions and procedures that are included in six studies. Data analysis was carried out using specialised software. The meta-analysis results showed pooled mean differences in weight change of -5.4 kg (95% CI: -5.8, -5.0), in waist circumference change of -5.5 cm (95% CI: -7.7, -3.25), and in weight loss as a percentage from baseline of -7.75% (95% CI: -11.1, -4.3). Quality assessment and bias of each study have been reported. Nutrition practice guidelines and MNT are also listed to include screening, assessment, intervention, and monitoring. Based on current available evidence, using GLP-1 agonists for weight loss shows their effectiveness to reduce weight and waist circumference. However, further incorporation of RD in trials will help in understanding the sole effect of MNT in treating obesity using GLP-1 agonists.

营养学家在使用胰高血糖素样肽-1激动剂受体的成人肥胖无糖尿病患者体重管理中的作用:随机对照临床试验的系统评价和荟萃分析
目的是(1)确定和解释注册营养师在临床试验中对胰高血糖素样肽-1 (GLP-1)激动剂对肥胖但无糖尿病的成年个体的疗效的作用,(2)量化GLP-1激动剂对肥胖但无糖尿病的成年个体体重减轻的影响。使用PubMed和Scopus进行电子检索以定位符合条件的随机临床试验。对13项符合纳入标准的研究进行数据提取和质量评价。医学营养治疗(MNT)的步骤是根据注册营养师(RD)的干预措施和程序进行评估,这些措施和程序包括在六项研究中。数据分析使用专门的软件进行。荟萃分析结果显示,体重变化的平均差异为-5.4 kg (95% CI: -5.8, -5.0),腰围变化的平均差异为-5.5 cm (95% CI: -7.7, -3.25),体重减轻的平均差异为-7.75% (95% CI: -11.1, -4.3)。已报道了每项研究的质量评价和偏倚。还列出了营养实践指南和MNT,包括筛选、评估、干预和监测。根据现有的证据,使用GLP-1激动剂减肥显示出其减轻体重和腰围的有效性。然而,在试验中进一步纳入RD将有助于了解MNT在使用GLP-1激动剂治疗肥胖中的唯一作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical Obesity
Clinical Obesity ENDOCRINOLOGY & METABOLISM-
CiteScore
5.90
自引率
3.00%
发文量
59
期刊介绍: Clinical Obesity is an international peer-reviewed journal publishing high quality translational and clinical research papers and reviews focussing on obesity and its co-morbidities. Key areas of interest are: • Patient assessment, classification, diagnosis and prognosis • Drug treatments, clinical trials and supporting research • Bariatric surgery and follow-up issues • Surgical approaches to remove body fat • Pharmacological, dietary and behavioural approaches for weight loss • Clinical physiology • Clinically relevant epidemiology • Psychological aspects of obesity • Co-morbidities • Nursing and care of patients with obesity.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信